DR. FLORENTIA FOSTIRA

HOME ADDRESS: 67 SARANTOGLOU STREET, ATHENS, 14342, GREECE
TEL. +302102517452, MOBILE. +30 6937106978
EMAIL: florentia_fostira@hotmail.com

WORK ADDRESS: NCSR DEMOKRITOS
MOLECULAR DIAGNOSTICS LABORATORY
ATHENS, 15310, AGHIA PARASKEVI, GREECE
TEL. +302106503841, MOBILE. +30 6937106978
EMAIL: florentia@rrp.demokritos.gr

EDUCATION

INSTITUTE/UNIVERSITY	DEGREE	DURATION	FIELD OF STUDY
School of Biomedical Sciences, King's College London, London, UK	BSc (2ii)	09/2000-06/2003	Molecular Biology
Department of Medicine, Imperial College London, London, UK	MSc	09/2003-09/2004	Molecular Medicine
Department of Medicine, University College London, London, UK	Training	11/2004-01/2006	Insulin cell signaling
Molecular Diagnostics Laboratory, NCSR Demokritos & Molecular Biology & Genetics Department, Democritus University of Thrace	PhD	01/2006-03/2010	Cancer Genetics: Genetic analysis in hereditary colorectal cancer

06/2017: European Registered as European Clinical Laboratory Geneticist (ErCLG) from the European Board of Medical Genetics (EBMG).
09/2020-today: MSc in Genetic and Genomic Counselling, Cardiff University, UK

SCIENTIFIC CAREER

03/2020-today: Researcher, Faculty Member, InRASTES, NCSR «DEMOKRITOS»
07/2017-today: Adjunct Researcher, Molecular Diagnostics Laboratory, NCSR «DEMOKRITOS»
02/2017-09/2017_02/2018-09/2017: Lecturer, Biology Department,University of Patras
10/2014 – 07/2017: Junior Researcher, Molecular Diagnostics Laboratory,NCSR «DEMOKRITOS»
12/10/2010–12/10/2014: Post-Doctoral Research Fellow, MolecularDiagnostics Laboratory, NCSR «DEMOKRITOS»
4/2/2013 – 4/4/2013: Visiting Researcher, Professor Mary-Claire King Laboratory, Department of Genome Sciences and Medicine, University of Washington, Seattle
7/1/2010 – 6/9/2010: Post-Doctoral Researcher, Molecular Diagnostics Laboratory, NCSR «DEMOKRITOS»

SCHOLARSHIPS/FELLOWSHIPS

- ✓ 4-year Fellowship (Adjunct Researcher) from 'Stavros Niarchos' Foundation
- ✓ European Fellowship for participation in the course 'Basics in Human Genetic Diagnostics'of European Society of Human Genetics (Nicosia, 2016)
- ✓ National Fellowship Award for participation in European Society of Human GeneticsConference (Nuremberg, 2012)
- ✓ National Fellowship Travel Award for participation in Mediterranean Medical GeneticsConference (Ankara, 2009)

AWARDS

1. L'OREAL-UNESCO AWARD FOR WOMEN IN SCIENCE – Greece Laureate for Science Accomplishements (Athens, Greece, December 2014).
2. BEST ORAL PRESENTATION at Panhellenic Breast Surgery Conference - "Multidisciplinary Approach as a tool for precision medicine'' (Athens, December 2019).
3. BEST ORAL PRESENTATION at the 60th Hellenic Oncology Symposium – ''High prevalence of pathogenic variants in epithelial ovarian cancer patients'' (Athens, May 2019).
4. BEST ORAL PRESENTATION at 2nd Mediterranean Multidisciplinary Forum Congress - "Prevalence of *BRCA1* mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria'' (Instabul, Turkey, November 2011).
5. BEST ORAL PRESENTATION at 31st PanHellenic Gastroenterology Congress - "*CDH1* mutations that predispose for hereditary difuse gastric cancer (HDGC) among Greek families'' (Thessaloniki, Greece, October 2011).
6. BEST RESEARCH PROJECT AWARD "Sotiris Papastamatis" awarded by the Medical Society oif Athens - "Genetic elucidation in a family with strong family history of breast and ovarian cancer,negative for *BRCA1 & BRCA2* mutations'' (Athens, Greece, December 2009).
7. BEST ORAL PRESENTATION at 4th International Congress on Gastrointestinal Oncology - "Autosomal recessive inherited mutations of *MUTYH* predispose to colorectal adenomatous polyposis'' (Athens, Greece, May 2009).
8. BEST ORAL PRESENTATION at3rd International Congress on Gastrointestinal Oncology - "Mutational Analysis of a typical HNPCC family'' (Herakleion, Greece, June 2007).

Peer-reviewed publications

Total number of publications: 109
Total citations: 5444, h-index: 31 / i10-index: 74
(Scopus, 26/10/2022 - Author ID: 57222590135 / ORCID ID: 0000-0003-2751-2332)

Selected publications

1. Fostira F, Konstantopoulou I. Variant Interpretation in Patients With Metastatic Breast Cancer. JAMA Oncol. 2020; doi:10.1001/jamaoncol.2019.6397.
2. Fountzilas E, Konstantopoulou I, Vagena A, Apostolou P, Papadimitriou C, Christodoulou C, Tryfonopoulos D, Manousou K, Delimitsou A, Fountzilas G, Yannoukakos D, Fostira F. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections. Clin Breast Cancer. 2020;20(2):152-159.
3. Fostira F, Kostantopoulou I, Apostolou P, Papamentzelopoulou MS, Papadimitriou C, Faliakou E, Christodoulou C, Boukovinas I, Razis E, Tryfonopoulos D, Barbounis V, Vagena A, Vlachos IS, Kalfakakou D, Fountzilas G, Yannoukakos D. One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene. J Med Genet. 2020;57(1):53-61.
4. Delimitsou A, Fostira F, Kalfakakou D, Apostolou P, Konstantopoulou I, Kroupis C, Papavassiliou AG, Kleibl Z, Stratikos E, Voutsinas GE, Yannoukakos D. Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system. Hum Mutat. 2019;40(5):631-648.
5. Fostira F, Kontopodis E, Apostolou P, Androulakis N, Yannoukakos D, Konstantopoulou I, Saloustros E. Extending the clinical phenotype associated with biallelic NTHL1 germline mutations. Clin Genet. 2018;94(6):588-589.
6. Fostira F, Mollaki V, Delimitsou A, Vlassi M, Pentheroudakis G, Faliakou E, Kollia P, Fountzilas G, Yannoukakos D, Konstantopoulou I. Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients. J Hum Genet. 2018; 63(8):877-886.
7. Fostira F, Saloustros E, Apostolou P, Vagena A, Kalfakakou D, Mauri D, Tryfonopoulos D, Georgoulias V, Yannoukakos D, Fountzilas G, Konstantopoulou I. Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer. Breast Cancer Res Treat. 2018; 169(1):105-113.
8. Fostira F, Mollaki V, Lypas G, Alexandrakis G, Christianakis E, Tzouvala M, Zacharopoulou E, Kalfakakou D, Konstantopoulou I, Yannoukakos D. Genetic analysis and clinical description of Greek patients with Peutz-Jeghers syndrome:Creation of a National Registry. Cancer Genet. 2018; 220:19-23.
9. Kotoula V^, Fostira F^, Papadopoulou K, Apostolou P, Tsolaki E, Lazaridis G, Manoussou K, Zagouri F, Pectasides D, Vlachos I, Tikas I, Lakis S, Konstantopoulou I, Pentheroudakis G, Gogas H, Papakostas P, Christodoulou C, Bafaloukos D, Razis E, Karavasilis V, Bamias C, Yannoukakos D, Fountzilas G. The fate of BRCA1-related germline mutations in triple-negative breast tumors. Am J Cancer Res. 2017; 7(1):98-114. ^equal
10. Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, Tomiak E, Neuhausen SL, Teo ZL, Khan S, Aittomäki K, Moilanen JS, Turnbull C, Seal S, Mannermaa A, Kallioniemi A, Lindeman GJ, Buys SS, Andrulis IL, Radice P, Tondini C, Manoukian S, Toland AE, Miron P, Weitzel JN, Domchek SM, Poppe B, Claes KB, Yannoukakos D, Concannon P, Bernstein JL, James PA, Easton DF, Goldgar DE, Hopper JL, Rahman N, Peterlongo P, Nevanlinna H, King MC, Couch FJ, Southey MC, Winqvist R, Foulkes WD, Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. New England Journal of Medicine 2014; 371(6): 497-506.
11. Fostira F, Konstantopoulou I, Mavroudis D, Tryfonopoulos D, Yannoukakos D, Voutsinas GE. Genetic evaluation based on family history and Her2 status correctly identifies TP53 mutations in very early onset breast cancer cases. Clinical Genetics 2014; 87(4): 383-7.
12. Fostira F, Tsitlaidou M, Papadimitriou C, Pertesi M, Timotheadou E, Stavropoulou AV, Glentis S, Bournakis E, Bobos M, Pectasides D, Papakostas P, Pentheroudakis G, Gogas H, Skarlos P, Samantas E, Bafaloukos D, Kosmidis PA, Koutras A, Yannoukakos D, Konstantopoulou I, Fountzilas G. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment 2012; 134(1): 353-62.52.

LECTURSHIPS/ EDUCATIONAL EXPERIENCE

- ✓ **One-day workshop on genetic testing and hereditary cancer for Hellenic Academy of Oncology:** *Seminary for young clinical oncologists on genetic testing and hereditary cancer with title: 'Detecting mutations in hereditary cancer.' Athens* 2018.
- ✓ **Workshop for the 2nd course of 'Basics in Human genetic diagnostics' (European Society of Human Genetics):** *Workshop for young scientists on Cancer Genetics Diagnostics, Reporting and databases for sequencing results. Athens* 2017.
- ✓ **Seminars for Hellenic Academy of Oncology:** *Seminary for young clinical oncologists on cancer genetics with title: 'Proto-oncogenes, oncogenes and tumor suppressor genes.' Athens* 2016.
- ✓ **European Learning Laboratory for the Life Sciences (ELLS) – organized by European Molecular Biology Laboratory (EMBL):** *Lecture for the basic principles of Genetics.* The audience were biology teachers. *Athens* 2015.

TRAINING IN CLINICAL GENETICS

06/2017-06/2021: Accredited as European Registered Clinical Laboratory Geneticist (ErCLG) from the European Board of Medical Genetics (EBMG).

09/2020-today: MSc in Genetic and Genomic Counselling, Cardiff University, UK.

TEACHING EXPERIENCE

02/2017-09/2017 & 02/2018-09/2018	**Lecturer** **University of Patras - Department of Biology** • Teach the one semester course of Human Genetics and Medical Genetics in 4-year Biology students. • Responsible for the guidance of students for their project assigments.
06/2017, 06/2018, 05/2019	**Lecturer** **University of Thessaly – Medical School** • Teach a three-hour lecture on Colorectal Cancer Genetics in on MSc of Human Genetics students
05/2017, 05/2019	**Lecturer** **University of Athens – Medical School** • Teach a three-hour lecture on Upper GI Cancer Genetics in on MSc of Surgical Oncology students.

REVIEWER IN SCIENTIFIC JOURNALS

- European Journal of Human Genetics
- Familial Cancer
- British Biotechnology Journal
- Journal of Human Genetics
- Molecular Biology Reports
- World Journal of Gastroenterology
- Molecular Diagnosis & Therapy
- BMC Medical Genetics
- Hereditary Cancer in Clinical Practice
- Clinical Breast Cancer
- Pathology, Research and Practice
- Journal of Ped. Gastroenterology and Nutrition
- Frontiers in Genetics

PARTICIPATION IN CONSORTIA

- Member of ENIGMA Consortium - Evidence-based Network for Interpretation of Genome Modifying Alterations
- Member of Triple Negative Breast Cancer Consortium (TNBC)
- Member of Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
- Member of Breast Cancer Association Consortium (BCAC)
- Member of Ovarian Cancer Association Consortium (OCAC)
- Member of *PALB2*-Interest Group

SCIENTIFIC MEMBER IN SOCIETIES

- ✓ European Society of Human Genetics
- ✓ American Society of Human Genetics
- ✓ Association of Medical Geneticist of Greece
- ✓ PESPA Greek Alliance for Rare Disease Network

PARTICIPATION IN SCIENTIFIC COMMITTEES

- ✓ Faculty member of the Scientific Committee of patient group with VHL (Von Hippel-Lindau) syndrome
- ✓ Faculty member of the Scientific Committee for consensus guidelines of *BRCA1* & *BRCA2* mutation carriers – Coordinated by Hellenic Society of Medical Oncologists.
- ✓ Faculty member of the Scientific Committee for consensus guidelines of hereditary colorectal cancer syndromes – Coordinated by Hellenic Society of Medical Oncologists.

NATIONAL AND INTERNATIONAL COLLABORATIONS

✓ *Hellenic Cooperative Oncology Group*

Network 80 oncologists from oncology clinics around Greec.

President: Professor Georgios Fountzilas, Honorary Professor of Medical School, Aristotle University of Thessaloniki

- Professor Fergus J. Couch, Ph.D. Chair, Department of Laboratory Medicine and Pathology Mayo Clinic, Rochester, USA
- Dr Marc Tischkowitz, Reader in Medical Genetics, University of Cambridge
- Prof. Mary-Claire King, University of Washington School of Medicine Seattle
- Prof. D. Goldgar, Department of Medical Informatics, University of Utah, Salt Lake City
- Drs J. Benitez & A. Osorio, Spanish National Cancer Centre - CNIO, Madrid, Spain
- Drs D. Hughes & O. Sinilnikova, International Agency for Research on Cancer, Lyon
- Dr. D. Stoppa-Lyonnet, Chef du Service de Génétique Oncologique de l'Institut Curie, Paris
- Prof. D. Easton & Dr A. Antoniou, University of Cambridge
- Dr G. Chenevix-Trench, Queensland Institute of Medical Research, Australia.
- Prof. W. Foulkes, Department of Human Genetics, McGill University, Canada
- Prof. T. Ozcelick, Bilkent University, Ankara
- Prof. P. Devilee, Univ. of Leiden NL
- Dr. K. Kyriacou, Cyprus Institute of Neurology & Genetics
- Prof. A. Monteiro, University of South Florida Cancer Biology Program, Tampa
- Drs Sinisa Radulovic & Mirjana Brankovic, Institute for Oncology and Radiology of Serbia

PARTICIPATION IN RESEARCH GRANTS

✓ **EREUNO– DIMIOURGO – KAINOTOMO**

"Decision Support system based on Radiogenomics for treatment management of patients with ovarian cancer". Duration: 2018-current.

Total Budget: €994.600.

✓ **ARISTEIA**

"Extreme Phenotypes in Breast-Ovarian Cancer: Whole exome analysis in very early onset (17-35yrs) cases". Duration: 2012-2015.

Total Budget: €401.592.

✓ **THALIS**

"Molecular Typing of Triple Negative Breast Cancer". Duration: 2012-2015.
Total Budget: €600.000.

✓ **SYNERGASIA II**

"Detection of New Breast and ovarian Cancer predisposing Alleles using whole genome next generation sequencing". Duration: 2012-2015.

Total Budget: €800.000.

FUNDING FROM ASSOCIATIONS AND PHARMA

- ✓ **Hellenic Cooperative Oncology Group-HeCOG:** Funding for research involving elucidation of hereditary cancer syndromes in Greece. Duration: 2008-2012. (Total Budget: €150.000).
- ✓ **PanHellenic Association of Women with Breast Cancer "Alma Zois":** Funding for providing *BRCA1* & *BRCA2* genetic testing in women with low income. Duration: 2010-2018. (Total Budget: €90.000).
- ✓ **Hellenic Society of Medical Oncologists (HeSMO):** "Funding for germline genetic testing by Next Generation Sequencing in ovarian cancer patients that will respond in targeted therapy". Duration: 2014-2015. (Total Budget €160.000).
- ✓ **AstraZeneca S.A.:** "Funding for germline and tumor genetic testing by Next Generation Sequencing in ovarian cancer patients that will respond in targeted therapy". Duration: 2017-current. (Total Budget €150.000).
- ✓ **AstraZeneca S.A.:** "Funding for germline and tumor genetic testing by Next Generation Sequencing in ovarian cancer patients that will respond in targeted therapy". Duration: 2017-2018. (Total Budget €150.000).
- ✓ **AstraZeneca S.A.:** "Genetic Signatures on ovarian cancer by Next Generation Sequencing navigate Precision Medicine". Duration: 2019-2020. (Total Budget €100.000).

THESES & PhD SUPERVISION

PhD theses - completed

- *Olga Triantafyllidou*

«Elucidating cancer predisposition of breast cancer, endometrial and ovarian cancer».
Completed June 2015.

- *Paraskevi Apostolou*

«Identification of new alleles in cancer genes predisposing for brest and ovarian cancer».
Completed September 2015.

PhD theses - ongoing

✓ ***Irene Konstanta*** «Genetic analysis in families with strong family history by Next Generation Sequencing».

✓ ***Andromahi Vagena*** «Detections and functional characterization of mutations in tumor suppressor genes».